Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

CR-000172

Investor Overview

Investor Overview

Corporate Profile

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

News Releases

Date Title and Summary Additional Formats
Toggle Summary Charles River and PathoQuest Strengthen Strategic Partnership
PathoQuest establishes U.S. subsidiary with state-of-the-art biologics genomic testing laboratory in Wayne, PA to expand its next-generation sequencing capabilities WILMINGTON, Mass. & PARIS--(BUSINESS WIRE)--Nov. 12, 2020-- PathoQuest SAS, a genomic expert company dedicated to quality control
View HTML
Toggle Summary Charles River Laboratories to Present at Upcoming Investor Conferences
WILMINGTON, Mass. --(BUSINESS WIRE)--Nov. 9, 2020-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at three upcoming investor conferences, including: Credit Suisse 29 th Annual Virtual Healthcare Conference on Tuesday, November 10 th , at
View HTML
Toggle Summary Charles River Laboratories Announces Third-Quarter 2020 Results
– Third-Quarter Revenue of $743.3 Million – – Third-Quarter GAAP Earnings per Share of $2.03   and Non-GAAP Earnings per Share of $2.33 – – Increases 2020 Guidance – WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 29, 2020-- Charles River Laboratories International, Inc.
View HTML
Toggle Summary Charles River Laboratories Adds George Llado to Board of Directors
WILMINGTON, Mass. --(BUSINESS WIRE)--Oct. 16, 2020-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of George Llado , Senior Vice President and Chief Information Officer of Alexion Pharmaceuticals, Inc., to its Board of Directors. Mr.
View HTML

Featured Report

2019 Annual Report (PDF)